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Received August 25, 2014; accepted April 26, 2016AbstractBackground: The exact pathogenesis of pterygium is still not fully understood. Growth factors are considered to play an important role in the
formation of pterygium. Transforming growth factor (TGF)-b1 is considered to be one of the main mediators of fibroblast stimulation and tissue
remodeling in allergic conditions. The objective of the present study was to investigate the association between TGF-b1 gene expression and
pterygium in atopic and nonatopic participants.
Methods: We used questionnaires to record demographic and clinical information from patients who underwent pterygium excision surgery. Skin
prick examination was done to confirm or rule out atopy in 30 patients with atopy (Case Group) and 30 individuals without atopy (Control
Group). Additionally, measurement of serum immunoglobulin E, cytokines, including interleukin-4 and interferon-g, and peripheral blood
eosinophil count was performed to confirm atopy in 30 consecutive patients (Case Group). A semiquantitative reverse transcription polymerase
chain reaction was performed to determine TGF-b1 gene expression in all individuals.
Results: TGF-b1 mRNA gene expression was significantly higher ( p ¼ 0.0001) in atopic patients 2.50 ± 1.11 compared to nonatopic individuals
1.40 ± 0.46. Eosinophil count and serum immunoglobulin E were significantly higher ( p ¼ 0.031 and p ¼ 0.001, respectively) in atopic patients
compared to the Control Group. Serum interleukin-4 was also significantly higher ( p ¼ 0.01) in atopic patients compared with nonatopic
individuals.
Conclusion: Excess expression of TGF-b1 gene in pterygium tissue of atopic individuals suggests that growth factors play a role in the
pathogenesis of pterygium.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pterygium is a benign condition, characterized by invasive
fibrovascular growth of the conjunctiva to the cornea, which is
generally linked with overexposure to UV radiation.1
Although some environmental factors (e.g., wind, dust, heat,
infection, smoke, chemicals, dry eye, and pollens) are sug-
gested to play a role in the pathogenesis of pterygium,1e3 the
exact etiology of this condition is still not fully understood.sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1













GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase; RT-PCR ¼ reverse
transcription polymerase chain reaction; TGF-b1 ¼ transforming growth
factor-b1.
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nological basis for the pathogenesis of pterygium.4,5 Several
growth factors, cytokines, and metalloproteinase enzymes are
identified in the cornea during the recovery time after photo-
refractive keratectomy. These biological factors, which are
produced by migratory leukocytes, are considered to play an
important role in the formation of pterygium.3 In addition, it
has been demonstrated that UV may activate signaling path-
ways in the epithelial cells of pterygium, resulting in pro-
duction of cytokines and growth factors.6
Both acute and chronic complications have been observed
in atopic patients due to the release of inflammatory mediators.
Transforming growth factor (TGF)-b1 is considered to be one
of the main mediators of tissue remodeling in patients with
asthma.7 It stimulates fibroblasts to produce extracellular
matrix proteins and cell-adhesion molecules such as collagen,
fibronectin, and integrins; decreases production of collage-
nase, heparinase, and stromelysin; and results in extracellular
matrix deposition. Additionally, it directly induces angiogen-
esis in vivo. Therefore, TGF-b1 is considered an effective
regulator of tissue invasion and metastasis.8 Stroma of pte-
rygium cells and fibroblasts plays a fundamental role in the
remodeling process of pterygium tissue. Matrix metal-
loproteinases have been found in these cells.9 Furthermore,
TGF-b1 enhances matrix metalloproteinase expression and
fibroblast activity.10
To the best of our knowledge, no previous investigation has
considered the association between pterygium and TGF-b1
levels in atopic patients. In the present study, TGF-b1 mRNA
gene expression in pterygium tissue of atopic patients was
evaluated to investigate its probable association with increased
susceptibility for pterygium formation. In addition, the present
study aimed to determine if TGF-b1 overexpression in atopic
individuals promotes tissue remodeling in pterygium forma-
tion. The histopathological differences in pterygium between
atopic and nonatopic patients have also been investigated.
2. Methods2.1. Study populationFig. 1. Transforming growth factor (TGF)-b1 gene expression compared with
the ladder was measured using reverse transcription polymerase chain reaction
(RT-PCR). RT-PCR products from TGF-b1 mRNA with 137-bp fragment (A)
and glyceraldehyde-3-phosphate dehydrogenase mRNAwith 266-bp fragment
(B) were separated on agarose gels and stained with green viewer. According
to the ManneWhitney U test, mean relative expression level of TGF-b1
mRNA was significantly higher ( p ¼ 0.0001) in atopic patients (2.50 ± 1.11)
compared with that in nonatopic individuals (1.40 ± 0.46).This study was conducted in accordance with the Helsinki
Declaration of 1975 (as revised in 1983) and approved by the
Research Ethics Committee of Islamic Azad University of
Mashhad, Mashhad, Iran. Informed consent was obtained from
all participants after the nature of the study was explained.
Predesigned questionnaires were used to record demographic
information and past medical history of individuals who were
diagnosed with pterygium and referred to the Eye Hospital of
Mashhad University of Medical Sciences from June 2010 to
May 2011. Thereafter, 30 pterygium patients without any
history of allergic reactions were enrolled in the Control
Group. Those with a history of at least one allergic condition
(e.g., asthma, allergic rhinitis, atopic dermatitis, hives or
angioedema, or food allergies) underwent skin prick testing
and measurement of total serum immunoglobulin (Ig)E level.
Correspondingly, 30 pterygium patients with positive skinprick test and IgE level > 100 IU/mL were included in the
Case Group. According to ophthalmological examination,
surgical excision of pterygium was performed on all 60 pa-
tients who were enrolled in the study. The exclusion criteria
were previous treatment with corticosteroids during the past
2 months, immunodeficiency, and absence of indication for
excisional surgery. Participants aged  60 years were also
excluded from the study population due to decreased wheal
and flare in skin prick tests.11 In addition, patients were
advised to withdraw from the use of drugs and medications at
least 48 hours before the skin test because some topical cor-
ticosteroids or antihistamines may affect the validity of skin
prick tests.12 Additionally, we certify that all applicable
institutional and governmental regulations concerning the
ethical use of human volunteers were followed during this
research.2.2. Immunological assessmentAll patients were evaluated by skin prick test on the inner
forearm, using 19 common standard allergen extracts (Stal-
lergenes, Antony, France; HollistereStier Laboratories, Spo-
kane, WA, USA). Blood samples were obtained by
Fig. 2. Comparison of serum cytokines interleukin (IL)-4 (A), interferon
(IFN)-g (B), and total immunoglobulin (Ig)E (C) levels between pterygium
patients with (n ¼ 30) and without (n ¼ 30) atopy. Cytokines and total IgE
levels were measured by enzyme-linked immunoassay. Data are
mean ± standard error. (A) Mean serum level of IL-4 in atopic patients
(3.43 ± 1.98 pg/mL) was significantly higher ( p ¼ 0.01) than in nonatopic
individuals (2.09 ± 2.18 pg/mL). (B) Mean serum level of IFN-g in atopic
patients (1.06 ± 1.39 pg/mL) did not differ significantly ( p ¼ 0.06) from that
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eosinophil count was measured using a Sysmex KX-21N cell
counter (Sysmex Corporation, Kobe, Japan). Aliquots of
serum were stored at 70C until analyzed for cytokines and
IgE level. Enzyme-linked immunosorbent assay was per-
formed to determine serum IgE levels (Monobind, Lake For-
est, CA, USA) and interleukin (IL)-4 and interferon (IFN)-g
(Amersham BioSciences, Little Chalfont, Buckinghamshire,
UK). Thirty individuals with positive skin prick tests and
serum IgE > 100 IU/mL were classified as atopic and included
in the Case Group.2.3. RNA extraction and reverse transcription
polymerase chain reactionAfter pterygium excision surgery, the tissues were collected
and immersed in RNA later solution at 20C until extraction.
An expert clinical pathologist histologically confirmed all
specimens as pterygium. RNeasy Kit (Fibrous Tissue, Qiagen,
Hilden, Germany) was used for purification of total RNA from
pterygium biopsy samples. Also, the quality and quantity of
the RNAwas photometrically confirmed. Subsequently, cDNA
was generated with Oligo-dt16 (Pars Tous, Iran). Reverse
transcription polymerase chain reaction (PCR) was performed
in a total volume of 20 mL containing 2 mL 10  PCR buffer,
2 mmol/L magnesium chloride, 0.2 mmol/L dNTP mixture,
1.5 U Hot-Start Taq DNA polymerase, 0.5 mmol/L each
primer, and 2 mL cDNA. A fragment of TGF-b1 gene (137 bp)
was amplified in the following PCR conditions: 30 seconds at
94C (denaturation), 30 seconds at 60C (annealing), and
30 seconds at 72C (extension) for 35 cycles with the primers
listed in Table 1.
To normalize expression of TGF-b1 mRNA, a 266-bp
fragment length of glyceraldehyde-3-phosphate dehydroge-
nase was amplified as follows: 30 seconds at 94C (denatur-
ation), 30 seconds at 56C (annealing), and 30 seconds at 72C
(extension) for 35 cycles with the primers listed in Table 1. A
2.5% agarose gel was used to separate PCR products and to
visualize under UV illumination, stained with green viewer
(Pars Tous). The mRNA expression of each gene was deter-
mined using Kodak 1D Image Analysis Software (Kodak,
Stuttgart, Germany). The band intensity was demonstrated as
an absolute integrated optical density. The integrated optical
density of each PCR product was normalized to that of glyc-
eraldehyde-3-phosphate dehydrogenase for the same biopsy
sample (Fig. 1A and 1B).2.4. Statistical analysisData were analyzed using SPSS version 18 (IBM Corpo-
ration, Armonk, NY, USA) and displayed as mean ± standard
deviation. To check the normality of the data, the Kolmogor-
oveSmirnov and Lilliefors test (for the correction of p valuesin nonatopic individuals (1.18 ± 0.74 pg/mL). (C) Mean serum level of IgE in
atopic patients (170.04 ± 65.0 IU/mL) was significantly higher ( p ¼ 0.001)
than that in nonatopic individuals (32.21 ± 15.96 IU/mL).
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test was performed for data with normal distribution, and the
ManneWhitney U test was used to compare non-normal
variables. Statistical analyses for the distributions of optical
densities in pterygium patients with and without atopy were
carried out using the c2 test or Fisher's exact test. A p
value < 0.05 was considered statistically significant.
3. Results
Mean ± standard deviation of age in patients with and
without atopy were 52.2 ± 12.0 years and 53.4 ± 16.6 years,
respectively. In both groups, 21 individuals were male (70.0%)
and nine were female (30.0%). Considering age and gender, no
statistically significant difference was noted between the
groups. Eosinophil count was significantly higher ( p ¼ 0.031)
in atopic patients (1.87 ± 0.73  109/L) compared to non-
atopic individuals (1.47 ± 0.51  109/L). Similarly, serum IgE
level was significantly higher ( p ¼ 0.001) in atopic patients, as
it was 170.04 ± 65.00 IU/mL in allergic patients compared
with 32.21 ± 15.96 units/mL in the Control Group (Fig. 2C).
As illustrated in Fig. 2, the Student t test confirmed that
serum IL-4 was significantly higher ( p ¼ 0.01) in atopic pa-
tients (3.43 ± 1.98 pg/mL) compared with nonatopic in-
dividuals (2.09 ± 2.18 pg/mL). However, no significant
difference was found ( p ¼ 0.06) in the serum IFN-g level
between the two groups (1.06 ± 1.39 pg/mL in the Case Group
and 1.18 ± 0.74 pg/mL in the Control Group; Fig. 2A and 2B).
Results from the ManneWhitney U test demonstrated that
the mean relative expression level of TGF-b1 mRNA was
significantly higher ( p ¼ 0.0001) in atopic patients
(2.50 ± 1.11) compared with nonatopic individuals
(1.40 ± 0.46; (Fig. 1A).
Finally, the eosinophils and mast cells in pterygium tissues of
atopic patients were higher; however, these changes did not reach
statistical significance in any cytological contents in pterygium
tissues of patients with and without atopy (data not shown).
4. Discussion
In this study, expression of TGF-b1 mRNA in pterygium
tissues of atopic patients was significantly higher than in
nonatopic individuals. Although the pathogenesis of pteryg-
ium is still not completely understood, some risk factors such
as UV light exposure, immunoinflammatory processes, viral
infections, and DNA damage are suggested to play a role.13 In
addition, pterygium can be considered as a benign neoplastic
condition due to the local invasion, epithelial cell metaplasia,
and abnormal expression of p53 tumor suppressor gene, which
are found in pterygium tissue.14e17
High levels of TGF-b1 suppress the immune response and
increase tumor invasiveness (metastasis), cell motility, angio-
genesis, and interaction of tumor cells with the extracellular
matrix.8 Therefore, it is proposed that the increased level of
TGF-b1 is an indicator of invasiveness of various late-stage
cancers.18,19 In the present study, the relative increase in the
level of TGF-b1 mRNA among pterygium patients with atopysuggests one possible explanation for the promotion of pte-
rygium growth. Meanwhile, it is well established that UV,
smoke, and pollens are major risk factors in the etiology of
pterygium. The pathogenesis of pterygium is that TGF-b1
worsens the pathology that has already been shown by other
risk factors such as UV light, smoke, pollens, and viruses.
TGF-b1 suppresses tumorigenesis; however, after tumor cells
become resistant to growth inhibition, overexpression of TGF-
b1 results in angiogenesis, invasion, and excess production of
extracellular matrix.
Expression of TGF-b1 gene is correlated with tissue
fibrosis and airway remodeling.20 In addition, TGF-b1, tumor
necrosis factor-a, IL-4, and histamine release in vernal kera-
toconjunctivitis are responsible for the previously described
pathological changes such as fibrillar collagen production,
giant papillae formation, and conjunctival tissue remodeling.21
Based on the current results, it may be concluded that TGF-b1
as a potent mediator of tissue remodeling can induce patho-
logical changes, such as fibrovascular advancement and elas-
totic degeneration, which are found in pterygium.
TGF-b1 also plays an important role in wound healing. It
stimulates fibroblasts to proliferate, migrate, and gradually
make a collagenous matrix in the wound tissue. However,
TGF-b1, along with insulin-like growth factor 1 and IL-1, may
result in fibroproliferative disorders such as keloids and hy-
pertrophic scars. Inflammation, remodeling of the wound
matrix, increased synthesis of extracellular-matrix proteins
and fibrogenic cytokines, abnormalities in cell migration and
proliferation, and increased response to cytokines are consid-
ered responsible for these conditions.22 It has been shown that
photoreactive keratectomy can induce rapid growth of pte-
rygium, possibly because of the existence of several fibrogenic
cytokines during the recovery period.3
Finally, we suggest that one possible mechanism of pte-
rygium formation is through fibrogenic cytokines such as
TGF-b that it promotes with atopic conditions. Therefore,
physicians should consider incorporating into their therapies
inhibition of the effect of growth factors after pterygium tissue
excision, before or after surgery, to reduce the recurrence rate
of this condition.
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